



5 May 2020

ASX Market
Announcements ASX
Limited
Level 4, Exchange
Centre 20 Bridge Street
Sydney, NSW 2000

Notice under section 708AA(2)(f) of the *Corporations Act 2001* (Cth)

Elixinol Global Limited (ASX Code: EXL)

This notice is given by Elixinol Global Limited (ACN 621 479 794) (**Elixinol**) under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Act**), as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84 and ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73.

Elixinol has announced a pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of 1 fully paid ordinary share in Elixinol (**New Share**) for every 2.51 Elixinol ordinary shares held as at 7.00 pm (AEST) on Thursday, 7 May 2020 by shareholders with a registered address in Australia, New Zealand and certain other jurisdictions in which Elixinol decides to extend the Entitlement Offer.

A Retail Entitlement Offer Booklet for the Entitlement Offer is expected to be dispatched to eligible retail shareholders on Tuesday, 12 May 2020.

Elixinol advises that:

1. the New Shares will be offered for issue without disclosure to investors under Part 6D.2 of the Act;
2. this notice is being given under section 708AA(2)(f) of the Act;
3. as at the date of this notice, Elixinol has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to Elixinol; and
 - b. section 674 of the Act;

4. as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Act that is required to be set out in this notice under section 708AA(7) of the Act; and
5. the potential effect that the Entitlement Offer will have on the control of Elixinol, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. However, given:
 - a. the structure of the Entitlement Offer as a pro rata issue;
 - b. the current level of holdings of substantial holdings (based on substantial holding notices that have been given to Elixinol and lodged with ASX on or prior to the date of this notice);
 - c. the two largest substantial shareholders of Elixinol, Raw with Life Pty Ltd (Benhaim Trading A/C) and D & G Health LLC, have informed Elixinol that they do not intend to take up their entitlements and will each hold approximately 28.3% and 6.5% respectively on completion of the Entitlement Offer,

the issue of New Shares under the Entitlement Offer is not expected to have any material effect or consequence on the control of Elixinol.

Yours faithfully



Teresa Cleary
General Counsel & Company Secretary
Elixinol Global Limited